Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases
- 16 November 2007
- journal article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (12) , 1716-1717
- https://doi.org/10.1136/bjo.2006.108639
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004